

(Under Corporate Insolvency Resolution Process)

December 10, 2019

National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th Floor, Plot No:
C/1, G - Block, Bandra - Kurla
Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: ORCHIDPHAR

BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001
BSE Code: 524372

Sub: Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on September 30, 2019.


Dear Sir/Madam

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we hereby submit the disclosure of Related Party transactions for the half year ended September 30, 2019.

Kindly take the above on your records.

Thanking you

Yours faithfully


S Mathanagopalan
General Manager-Finance

Orchid Pharma Limited

a) List of parties having significant influence

Holding company	The Company does not have any holding company
Subsidiary Company	Orchid Europe Limited, UK Orchid Pharmaceuticals Inc., USA Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc USA.) Orchid Pharma Inc / Karalex Pharma USA, (Subsidiary of Orchid Pharmaceuticals Inc, USA) Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa Bexel Pharmaceuticals Inc., USA Diakron Pharmaceuticals Inc., USA
Key management personnel (KMP)	Mr. K. Raghavendra Rao, Managing Director Mr. L. Chandrasekar, Executive VP-Finance & Secretary
Relatives of KMP	Mrs. R Vijayalakshmi, wife of Mr. K Raghavendra Rao Ms R Divya and Ms R Sowmya, daughters of Mr. K. Raghavendra Rao
Entities in which relatives of KMP exercise significant influence	Orchid Healthcare Private Ltd.

b) Transactions during the period 01.04.2019 to 30.09.2019

S.No.	Nature of transactions	H1 FY 2019-20	Year ended March 31, 2019
1	Unsecured advance Orchid Pharma Inc.	52.94	-
2	Sale of goods Orchid Pharma Inc.	351.85	536.78
3	Availment of services/ reimbursement Orchid Europe Limited	38.11	12.24
4	Remuneration and contribution to funds K. Raghavendra Rao L. Chandrasekar*	10.25 13.69	48.92 47.61

*Retired from Service on 30/06/2019

c) Balances at the end of the year

S.No.	Nature of transactions	As at Sep 30, 2019	As at March 31, 2019
1	Trade receivables Orchid Pharma Inc.	2,526.88	2,127.93
2	Loans and advances (Current) * Bexel Pharmaceuticals Inc., USA Diakron Pharmaceuticals Inc., USA Orchid Pharma Inc.	3,585.47 3.28 1,640.61	3,585.47 3.28 1,640.61
3	Short term borrowings Orchid Healthcare Private Ltd.	3,216.77	3,216.77
4	Trade payables Orchid Europe Limited Bexel Pharmaceuticals Inc., USA Orgenus Pharma Inc., USA	24.91 274.05 71.74	32.85 266.52 69.77

* Provision has been made for the entire outstanding amount during the year.